Published in World J Surg on November 01, 2012
DNMT1 is regulated by ATP-citrate lyase and maintains methylation patterns during adipocyte differentiation. Mol Cell Biol (2013) 1.01
Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer. Adv Drug Deliv Rev (2014) 1.00
MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer. World J Gastroenterol (2014) 0.98
MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets? Oncotarget (2015) 0.98
An emerging role for long non-coding RNAs in cancer metastasis. Front Genet (2014) 0.95
Regulatory circuit of PKM2/NF-κB/miR-148a/152-modulated tumor angiogenesis and cancer progression. Oncogene (2015) 0.93
MicroRNAs (miRNAs) as biomarker(s) for prognosis and diagnosis of gastrointestinal (GI) cancers. Curr Pharm Des (2014) 0.90
New targeted therapies in pancreatic cancer. World J Gastroenterol (2015) 0.87
Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer. Drug Des Devel Ther (2015) 0.85
A genetic variant of miR-148a binding site in the SCRN1 3'-UTR is associated with susceptibility and prognosis of gastric cancer. Sci Rep (2014) 0.83
MicroRNAs in Pancreatic Cancer: Involvement in Carcinogenesis and Potential Use for Diagnosis and Prognosis. Gastroenterol Res Pract (2015) 0.82
Identification of a novel microRNA signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis. BMC Cancer (2015) 0.82
A two-microRNA signature as a potential biomarker for early gastric cancer. Oncol Lett (2014) 0.82
miR-675-5p enhances tumorigenesis and metastasis of esophageal squamous cell carcinoma by targeting REPS2. Oncotarget (2016) 0.81
Emerging roles of microRNAs in pancreatic cancer diagnosis, therapy and prognosis (Review). Int J Oncol (2015) 0.81
MicroRNA-187 inhibits tumor growth and invasion by directly targeting CD276 in colorectal cancer. Oncotarget (2016) 0.80
MicroRNA-944 Affects Cell Growth by Targeting EPHA7 in Non-Small Cell Lung Cancer. Int J Mol Sci (2016) 0.79
Up-regulation of miR-187 modulates the advances of oral carcinoma by targeting BARX2 tumor suppressor. Oncotarget (2016) 0.77
MicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability. BMC Cancer (2015) 0.77
Down-Regulation of miR-148a Promotes Metastasis by DNA Methylation and is Associated with Prognosis of Skin Cancer by Targeting TGIF2. Med Sci Monit (2015) 0.77
Prospects of miRNA-based therapy for pancreatic cancer. Curr Drug Targets (2013) 0.76
Retracted MicroRNA-212 targets FOXA1 and suppresses the proliferation and invasion of intrahepatic cholangiocarcinoma cells. Exp Ther Med (2016) 0.75
Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers. Biomark Res (2017) 0.75
Prognostic role of microRNA-203 in various carcinomas: evidence from a meta-analysis involving 13 studies. Springerplus (2016) 0.75
miR-944 inhibits metastasis of gastric cancer by preventing the epithelial-mesenchymal transition via MACC1/Met/AKT signaling. FEBS Open Bio (2017) 0.75
The significance of microRNA-148/152 family as a prognostic factor in multiple human malignancies: a meta-analysis. Oncotarget (2017) 0.75
miR-187 inhibits tumor growth and invasion by directly targeting MAPK12 in osteosarcoma. Exp Ther Med (2017) 0.75
Characterization of a novel panel of plasma microRNAs that discriminates between Mycobacterium tuberculosis infection and healthy individuals. PLoS One (2017) 0.75
MiR-187 overexpression inhibits cervical cancer progression by targeting HPV16 E6. Oncotarget (2017) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
RAS is regulated by the let-7 microRNA family. Cell (2005) 30.24
The lasso method for variable selection in the Cox model. Stat Med (1997) 18.10
Pancreatic cancer. N Engl J Med (2010) 13.88
MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA (2007) 9.97
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol (2006) 7.43
miRNAs in human cancer. J Pathol (2010) 6.02
MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol (2009) 5.92
MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene (2007) 4.46
REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat (2006) 4.42
Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol (2007) 4.40
Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg (2004) 3.90
MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) (2009) 3.55
MiRNAs and cancer. Am J Pathol (2009) 3.42
MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab (2008) 3.40
Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol (2006) 3.37
Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer (2010) 3.11
MicroRNAs: novel biomarkers for human cancer. Clin Chem (2009) 2.97
MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res (2011) 2.95
MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg (2008) 2.86
Predicting survival from microarray data--a comparative study. Bioinformatics (2007) 2.80
Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis (2009) 2.45
Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg (2009) 2.31
Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene (2005) 2.14
MicroRNAs and cancer: past, present, and potential future. Mol Cancer Ther (2008) 2.05
MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther (2009) 2.01
Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One (2010) 1.96
Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem (2008) 1.87
An array-based analysis of microRNA expression comparing matched frozen and formalin-fixed paraffin-embedded human tissue samples. J Mol Diagn (2008) 1.82
Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One (2010) 1.77
Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am J Transl Res (2010) 1.74
Data-driven normalization strategies for high-throughput quantitative RT-PCR. BMC Bioinformatics (2009) 1.71
let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Hum Gene Ther (2009) 1.58
MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin Cancer Res (2011) 1.57
MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Mod Pathol (2012) 1.43
The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. Clin Chem (2010) 1.37
Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig Dis Sci (2010) 1.35
MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma. Ann Surg Oncol (2010) 1.25
Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma. Dig Surg (2008) 1.22
Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Mol Cancer Ther (2010) 1.20
Gene expression profiles of microdissected pancreatic ductal adenocarcinoma. Virchows Arch (2003) 1.18
MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications. Cancer Lett (2009) 1.01
Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas. Pancreas (2012) 0.97
MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. Ann Surg Oncol (2011) 0.93
Pathogenesis and treatment of neoplastic diseases of the papilla of Vater: Kausch-Whipple procedure with lymph node dissection in cancer of the papilla of Vater. J Hepatobiliary Pancreat Surg (2004) 0.92
MicroRNAs in pancreatic ductal adenocarcinoma: new diagnostic and therapeutic clues. Pancreatology (2008) 0.86
Presentation, treatment and outcome in patients with ampullary tumours. Br J Surg (2004) 0.82
Prediction of lipoprotein signal peptides in Gram-negative bacteria. Protein Sci (2003) 6.85
Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev (2006) 1.74
MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Mod Pathol (2012) 1.43
High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res (2003) 1.42
Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. Cancer Res (2011) 1.41
Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis (2013) 1.33
YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. Clin Diagn Lab Immunol (2002) 1.29
Investigation of potential non-HLA rheumatoid arthritis susceptibility loci in a European cohort increases the evidence for nine markers. Ann Rheum Dis (2010) 1.25
Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate (2006) 1.24
Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer (2005) 1.22
Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol (2003) 1.18
High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer (2002) 1.18
Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis. Biomarkers (2008) 1.18
Perforated peptic ulcer: how to improve outcome? Scand J Gastroenterol (2009) 1.16
Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes (2008) 1.14
High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J (2009) 1.12
Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci (2005) 1.10
IL-6, but not TNF-α, increases plasma YKL-40 in human subjects. Cytokine (2011) 1.09
High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol Rep (2003) 1.09
Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis (2008) 1.08
Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother (2008) 1.07
The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure. Rheumatology (Oxford) (2013) 1.07
Plasma YKL-40 levels in healthy subjects from the general population. Clin Chim Acta (2011) 1.07
Improving comparability between microarray probe signals by thermodynamic intensity correction. Nucleic Acids Res (2007) 1.05
Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother (2007) 1.05
Stroke and long-term exposure to outdoor air pollution from nitrogen dioxide: a cohort study. Stroke (2011) 1.05
High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia. Clin Cancer Res (2005) 1.04
Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol (2006) 1.04
Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. Cancer Causes Control (2013) 1.03
Genome update: distribution of two-component transduction systems in 250 bacterial genomes. Microbiology (2005) 1.02
Elevated plasma YKL-40 levels and ischemic stroke in the general population. Ann Neurol (2010) 1.01
Serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bacteremia and is associated with the outcome of the disease. Scand J Infect Dis (2002) 1.00
Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFα inhibitors in patients with rheumatoid arthritis. Pharmacogenet Genomics (2012) 1.00
Is YKL-40 a new therapeutic target in cancer? Expert Opin Ther Targets (2007) 1.00
Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer (2010) 0.99
Effect of mindfulness-based stress reduction on sleep quality: results of a randomized trial among Danish breast cancer patients. Acta Oncol (2013) 0.98
YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer (2009) 0.97
Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma. Clin Cancer Res (2008) 0.97
Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. Acta Obstet Gynecol Scand (2013) 0.97
Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas. Pancreas (2012) 0.97
Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome. J Rheumatol (2008) 0.97
YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer. Breast Cancer Res Treat (2007) 0.96
Functional Associations by Response Overlap (FARO), a functional genomics approach matching gene expression phenotypes. PLoS One (2007) 0.95
YKL-40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial Cystitis. Histopathology (2010) 0.94
YKL-40 protein expression in normal adult human tissues--an immunohistochemical study. J Mol Histol (2007) 0.93
Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy (2010) 0.93
Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Acta Obstet Gynecol Scand (2003) 0.93
YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. Methods Mol Biol (2009) 0.91
YKL-40 is differentially expressed in human embryonic stem cells and in cell progeny of the three germ layers. J Histochem Cytochem (2011) 0.90
High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival. Int J Cancer (2008) 0.89
Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. Melanoma Res (2012) 0.89
The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure. Immunobiology (2011) 0.89
High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients. Eur J Haematol (2007) 0.88
Hospital contact for mental disorders in survivors of childhood cancer and their siblings in Denmark: a population-based cohort study. Lancet Oncol (2013) 0.88
Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction. Scand J Clin Lab Invest (2010) 0.87
Genome update: sigma factors in 240 bacterial genomes. Microbiology (2005) 0.87
Living alone, obesity and smoking: important factors for quality of life after radiotherapy and androgen deprivation therapy for prostate cancer. Acta Oncol (2012) 0.87
Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjects. Arthritis Res Ther (2011) 0.86
Plasma YKL-40 is elevated in patients with recurrent atrial fibrillation after catheter ablation. Inflamm Res (2009) 0.86
Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer. PLoS One (2013) 0.86
Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease. Scand J Clin Lab Invest (2011) 0.86
The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease. Inflamm Res (2010) 0.85
Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial. Immunobiology (2012) 0.85
Malignant gastric outlet obstruction managed by endoscopic stenting: a prospective single-centre study. Scand J Gastroenterol (2009) 0.85
Development and validation of a Meal Index of dietary Quality (Meal IQ) to assess the dietary quality of school lunches. Public Health Nutr (2012) 0.85
Genetic variants in CHI3L1 influencing YKL-40 levels: resequencing 900 individuals and genotyping 9000 individuals from the general population. J Med Genet (2013) 0.84
YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel) (2010) 0.83
Plasma YKL-40 and CHI3L1 in systemic inflammation and sepsis-experience from two prospective cohorts. Immunobiology (2013) 0.83
The prognostic value of YKL-40 concentrations in nonmyeloablative conditioning allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 0.83
Social position and referral to rehabilitation among cancer patients. Acta Oncol (2015) 0.82
YKL-40 expression in benign and malignant lesions of the breast: a methodologic study. Appl Immunohistochem Mol Morphol (2007) 0.82
CRP genotype and haplotype associations with serum C-reactive protein level and DAS28 in untreated early rheumatoid arthritis patients. Arthritis Res Ther (2014) 0.81
Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells. Eur J Haematol (2006) 0.81
Supraclavicular recurrence after early breast cancer: a curable condition? Breast Cancer Res Treat (2010) 0.81
Global features of the Alcanivorax borkumensis SK2 genome. Environ Microbiol (2007) 0.81
Serum YKL-40 and bone marrow angiogenesis in multiple myeloma. Int J Cancer (2009) 0.81
Brain barriers and a subpopulation of astroglial progenitors of developing human forebrain are immunostained for the glycoprotein YKL-40. J Histochem Cytochem (2014) 0.80
Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease. BMC Pulm Med (2013) 0.80
Lifestyle, family history, and risk of idiopathic Parkinson disease: a large Danish case-control study. Am J Epidemiol (2015) 0.79
Validation of a digital photographic method for assessment of dietary quality of school lunch sandwiches brought from home. Food Nutr Res (2013) 0.78
Role of human papillomavirus testing and cytology in follow-up after conization. Acta Obstet Gynecol Scand (2015) 0.78
Effectiveness of a Canteen Take Away concept in promoting healthy eating patterns among employees. Public Health Nutr (2011) 0.77
Increased risk for cancer among offspring of women with fertility problems. Int J Cancer (2013) 0.76
YKL-40 levels and atrial fibrillation in the general population. Int J Cardiol (2012) 0.76
Comment on 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'. Oncology (2011) 0.75
Safety and efficacy of Profermin® to induce remission in ulcerative colitis. World J Gastroenterol (2012) 0.75
CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis. PLoS One (2012) 0.75
Equity in the use of publicly subsidized psychotherapy among elderly Danish cancer patients--a register-based cohort study. Acta Oncol (2012) 0.75
Prognostic and predictive value of YKL-40 in stage IIB-III melanoma. Melanoma Res (2016) 0.75
[Signet ring cell carcinoma of the gallbladder]. Ugeskr Laeger (2012) 0.75
Serum YKL-40 for monitoring myocardial ischemia after revascularization in patients with stable coronary artery disease. Biomark Med (2014) 0.75
The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab. Int J Gynecol Cancer (2016) 0.75